The NCCN updated its guidelines to clarify the role of ctDNA as a biomarker for recurrence risk in colon and rectal cancer and for disease monitoring in Merkel cell carcinoma.
Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.